{"title":"1 型糖尿病患者的肥胖、代谢健康和糖尿病并发症。","authors":"Yuanjie Mao, Jen-Tzer Gau, Ning Jiang","doi":"10.1002/edm2.70017","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>The concept of metabolically healthy obesity (MHO) has not been studied in type 1 diabetes (T1D). By analysing datasets from the DCCT/EDIC study, we compared the development of diabetic complications by obesity and metabolic health over 30 years of follow up.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Insulin resistance was calculated by estimated glucose disposal rate (eGDR). The participants (<i>n</i> = 1127) were then divided into four groups based on time-weighted mean body mass index and mean eGDR: metabolically healthy non-obesity (MHN, <i>n</i> = 874), metabolically unhealthy non-obesity (MUN, <i>n</i> = 66), MHO (<i>n</i> = 146) and metabolically unhealthy obesity (MUO, <i>n</i> = 41). Diabetic complications and cardiovascular events were compared across the four groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>MUO and MUN groups had significantly higher risk for peripheral neuropathy (<i>p</i> = 0.001 in MUO and <i>p</i> < 0.001 in MUN vs. MHN), cardiac autonomic neuropathy (<i>p</i> < 0.001 in both MUO and MUN vs. MHN), retinopathy (<i>p</i> = 0.001 in MUO and <i>p</i> < 0.001 in MUN vs. MHN) and microalbuminuria (<i>p</i> < 0.001 in both MUO and MUN vs. MHN) than MHN group. Moreover, MUO and MUN groups had significantly higher risks (HR [95%CI]) in any cardiovascular events (2.78 [1.51–5.11] and 1.88 [1.05–3.36]) and major atherosclerotic cardiovascular events (2.72 [1.16–6.37] and 2.31 [1.05–5.10]) compared to MHN group. However, the risk of these complications and cardiovascular events (except peripheral neuropathy and cardiac autonomic neuropathy) in MHO group was not different from that in MHN group.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study highlights the importance of metabolic health represented by insulin resistance in the development of diabetic complications and cardiovascular events in T1D beyond their weight status.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70017","citationCount":"0","resultStr":"{\"title\":\"Obesity, Metabolic Health, and Diabetic Complications in People With Type 1 Diabetes\",\"authors\":\"Yuanjie Mao, Jen-Tzer Gau, Ning Jiang\",\"doi\":\"10.1002/edm2.70017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>The concept of metabolically healthy obesity (MHO) has not been studied in type 1 diabetes (T1D). By analysing datasets from the DCCT/EDIC study, we compared the development of diabetic complications by obesity and metabolic health over 30 years of follow up.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>Insulin resistance was calculated by estimated glucose disposal rate (eGDR). The participants (<i>n</i> = 1127) were then divided into four groups based on time-weighted mean body mass index and mean eGDR: metabolically healthy non-obesity (MHN, <i>n</i> = 874), metabolically unhealthy non-obesity (MUN, <i>n</i> = 66), MHO (<i>n</i> = 146) and metabolically unhealthy obesity (MUO, <i>n</i> = 41). Diabetic complications and cardiovascular events were compared across the four groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>MUO and MUN groups had significantly higher risk for peripheral neuropathy (<i>p</i> = 0.001 in MUO and <i>p</i> < 0.001 in MUN vs. MHN), cardiac autonomic neuropathy (<i>p</i> < 0.001 in both MUO and MUN vs. MHN), retinopathy (<i>p</i> = 0.001 in MUO and <i>p</i> < 0.001 in MUN vs. MHN) and microalbuminuria (<i>p</i> < 0.001 in both MUO and MUN vs. MHN) than MHN group. Moreover, MUO and MUN groups had significantly higher risks (HR [95%CI]) in any cardiovascular events (2.78 [1.51–5.11] and 1.88 [1.05–3.36]) and major atherosclerotic cardiovascular events (2.72 [1.16–6.37] and 2.31 [1.05–5.10]) compared to MHN group. However, the risk of these complications and cardiovascular events (except peripheral neuropathy and cardiac autonomic neuropathy) in MHO group was not different from that in MHN group.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This study highlights the importance of metabolic health represented by insulin resistance in the development of diabetic complications and cardiovascular events in T1D beyond their weight status.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36522,\"journal\":{\"name\":\"Endocrinology, Diabetes and Metabolism\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70017\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology, Diabetes and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的:代谢健康型肥胖(MHO)的概念尚未在1型糖尿病(T1D)中进行研究。通过分析DCCT/EDIC研究的数据集,我们在30年的随访中比较了肥胖和代谢健康引起的糖尿病并发症的发展。材料与方法:采用估计葡萄糖处置率(eGDR)计算胰岛素抵抗。参与者(n = 1127)根据时间加权平均体重指数和平均eGDR分为四组:代谢健康的非肥胖(MHN, n = 874),代谢不健康的非肥胖(MUN, n = 66), MHO (n = 146)和代谢不健康的肥胖(MUO, n = 41)。比较四组患者的糖尿病并发症和心血管事件。结果:MUO组和MUN组周围神经病变的风险显著增加(在MUO组和MUN组中p = 0.001)。结论:本研究强调了以胰岛素抵抗为代表的代谢健康在T1D患者体重之外糖尿病并发症和心血管事件发展中的重要性。
Obesity, Metabolic Health, and Diabetic Complications in People With Type 1 Diabetes
Aim
The concept of metabolically healthy obesity (MHO) has not been studied in type 1 diabetes (T1D). By analysing datasets from the DCCT/EDIC study, we compared the development of diabetic complications by obesity and metabolic health over 30 years of follow up.
Materials and Methods
Insulin resistance was calculated by estimated glucose disposal rate (eGDR). The participants (n = 1127) were then divided into four groups based on time-weighted mean body mass index and mean eGDR: metabolically healthy non-obesity (MHN, n = 874), metabolically unhealthy non-obesity (MUN, n = 66), MHO (n = 146) and metabolically unhealthy obesity (MUO, n = 41). Diabetic complications and cardiovascular events were compared across the four groups.
Results
MUO and MUN groups had significantly higher risk for peripheral neuropathy (p = 0.001 in MUO and p < 0.001 in MUN vs. MHN), cardiac autonomic neuropathy (p < 0.001 in both MUO and MUN vs. MHN), retinopathy (p = 0.001 in MUO and p < 0.001 in MUN vs. MHN) and microalbuminuria (p < 0.001 in both MUO and MUN vs. MHN) than MHN group. Moreover, MUO and MUN groups had significantly higher risks (HR [95%CI]) in any cardiovascular events (2.78 [1.51–5.11] and 1.88 [1.05–3.36]) and major atherosclerotic cardiovascular events (2.72 [1.16–6.37] and 2.31 [1.05–5.10]) compared to MHN group. However, the risk of these complications and cardiovascular events (except peripheral neuropathy and cardiac autonomic neuropathy) in MHO group was not different from that in MHN group.
Conclusions
This study highlights the importance of metabolic health represented by insulin resistance in the development of diabetic complications and cardiovascular events in T1D beyond their weight status.